Results 71 to 80 of about 13,422 (244)

Characterization of the Glycoproteins of Crimean-Congo Hemorrhagic Fever Virus [PDF]

open access: yesJournal of Virology, 2002
ABSTRACT Crimean-Congo hemorrhagic fever (CCHF) virus is the cause of an important tick-borne disease of humans throughout regions of Africa, Europe, and Asia. Like other members of the genus Nairovirus , family Bunyaviridae , the CCHF virus M genome RNA segment encodes the virus ...
Angela J. Sanchez   +2 more
semanticscholar   +3 more sources

Crimean–Congo Hemorrhagic Fever Virus in Bulgaria and Turkey

open access: yesVector-Borne and Zoonotic Diseases, 2016
Infections of humans with the tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV) can cause a severe hemorrhagic fever with case fatality rates of up to 80%. Most humans are infected by tick bite, crushing infected ticks by hand or by unprotected contact with blood of viremic mammals.
Mertens, Marc   +9 more
openaire   +4 more sources

Crimean Hemorrhagic Fever: Ecologic and Epizootic Role of the Corvidae Family

open access: yesПроблемы особо опасных инфекций, 2008
The role of birds in the circulation of the virus of Congo-Crimean hemorrhagic fever (CCHF) is described in the paper. Investigation of 758 samples of birds revealed the virus CCHF antigen to be present in 19 (2.51 % ± 0.57) rooks' samples. Corvidae were
S. Yu. Vodyanitskaya   +7 more
doaj   +1 more source

Crimean-Congo Hemorrhagic Fever Virus in Ticks from Migratory Birds, Morocco

open access: yesEmerging Infectious Diseases, 2013
Crimean-Congo hemorrhagic fever virus was detected in ticks removed from migratory birds in Morocco. This finding demonstrates the circulation of this virus in northwestern Africa and supports the hypothesis that the virus can be introduced into Europe ...
Ana M. Palomar   +8 more
doaj   +1 more source

Distribution of tick-borne diseases in China [PDF]

open access: yes, 2013
As an important contributor to vector-borne diseases in China, in recent years, tick-borne diseases have attracted much attention because of their increasing incidence and consequent significant harm to livestock and human health.
Hong-Juan Peng   +4 more
core   +1 more source

Cellular immune response of Amblyomma sculptum and Amblyomma americanum to entomopathogenic fungi: Implications for biological tick control

open access: yesMedical and Veterinary Entomology, EarlyView.
Amblyomma sculptum showed a plasmatocyte‐dominant haemocyte profile. Beauveria bassiana increased plasmatocytes and reduced granulocytes, whereas Metarhizium robertsii did not cause significant changes. Amblyomma americanum showed a granulocyte‐dominant haemocyte profile. Beauveria bassiana reduced total haemocytes and granulocytes. B.
Cárita de Souza Ribeiro‐Silva   +7 more
wiley   +1 more source

Crimean-Congo Hemorrhagic Fever in Bulgaria

open access: yesEmerging Infectious Diseases, 2004
We report the epidemiologic characteristics of Crimean-Congo hemorrhagic fever in Bulgaria, as well as the first genetic characterization of the virus strains circulating in the country in 2002–2003 that caused disease in humans.
Anna Papa   +3 more
doaj   +1 more source

Crimean‐Congo Haemorrhagic Fever Virus Exposure in Horses and Donkeys in Border Livestock Markets of Nigeria

open access: yesZoonoses and Public Health, EarlyView.
ABSTRACT Introduction Crimean‐Congo haemorrhagic fever virus (CCHFV) is a tick‐borne zoonotic pathogen of major public health importance in Africa. Although CCHFV exposure has been reported in several livestock species in Nigeria, data on equids remain limited despite their extensive involvement in livestock movement and trade.
David O. Ehizibolo   +14 more
wiley   +1 more source

Crimean-Congo Hemorrhagic Fever [PDF]

open access: yes, 2015
The Crimean-Congo Hemorrhagic Fever (CCHF) is a tick-borne infectious viral disease in the family Bunyaviridae. The disease was first characterized in the Crimea in 1944 and given the name Crimean hemorrhagic fever. CCHF was then later recognized in 1969
Ninan, Reuben
core   +2 more sources

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

Home - About - Disclaimer - Privacy